OKYO Pharma announces Gabriele Cerrone's acquisition of shares and progress on urcosimod for neuropathic corneal pain treatment.
Quiver AI Summary
OKYO Pharma Limited, a bio-pharmaceutical company focused on ophthalmology, announced that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, has acquired 82,018 shares of the company, increasing Cerrone's total holdings to over 10.4 million shares. OKYO is developing urcosimod, a novel treatment for neuropathic corneal pain (NCP), a condition for which there are currently no FDA-approved therapies. Urcosimod, a lipid-conjugated peptide designed to enhance therapeutic efficacy in the eye, has demonstrated significant anti-inflammatory and pain-relieving effects in clinical trials, including a recently completed Phase 2 trial for NCP. OKYO Pharma aims to address unmet needs in treating neuropathic corneal pain and dry eye disease.
Potential Positives
- Gabriele Cerrone, Executive Chairman, has increased his holding in OKYO Pharma, acquiring 82,018 additional shares, signaling confidence in the company's prospects.
- Urcosimod, the company’s lead candidate, demonstrated statistical significance in multiple endpoints during its recent Phase 2 trials, supporting its potential effectiveness for treating neuropathic corneal pain.
- OKYO Pharma is focused on addressing significant unmet medical needs with no FDA-approved therapies currently available for neuropathic corneal pain, positioning the company in a niche yet critical market.
- Urcosimod's development leverages innovative membrane-anchored-peptide technology, which may enhance its efficacy and competitiveness in the ophthalmology space.
Potential Negatives
- Gabriele Cerrone, the Executive Chairman, acquiring a significant number of shares could raise concerns regarding potential insider trading or conflicts of interest, particularly given his influential role in the company's decision-making processes.
- The company is still in clinical stages with no FDA-approved therapies, which may lead to uncertainties about future market viability and the success of their drug development efforts.
- The announcement does not highlight any successful outcomes from the recently completed Phase 2 trial for neuropathic corneal pain, potentially leaving investors uncertain about the effectiveness and future of the drug.
FAQ
What is urcosimod and its purpose?
Urcosimod is a drug candidate developed by OKYO Pharma to treat neuropathic corneal pain, an ocular condition lacking FDA-approved therapies.
How many shares has Gabriele Cerrone acquired?
Gabriele Cerrone has acquired 82,018 shares, increasing his total holding to 10,464,695 shares in OKYO Pharma.
What is the significance of the Phase 2 trial for urcosimod?
The Phase 2 trial for urcosimod showed statistical significance in multiple endpoints for treating neuropathic corneal pain.
What is the main focus of OKYO Pharma?
OKYO Pharma focuses on developing innovative therapies for neuropathic corneal pain and dry eye disease.
Where can I find more information about OKYO Pharma?
Further information can be found on OKYO Pharma's official website at www.okyopharma.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OKYO Hedge Fund Activity
We have seen 4 institutional investors add shares of $OKYO stock to their portfolio, and 4 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DAUNTLESS INVESTMENT GROUP, LLC removed 313,732 shares (-11.5%) from their portfolio in Q3 2025, for an estimated $627,464
- NORTHERN TRUST CORP added 57,158 shares (+inf%) to their portfolio in Q3 2025, for an estimated $114,316
- RENAISSANCE TECHNOLOGIES LLC added 41,200 shares (+inf%) to their portfolio in Q3 2025, for an estimated $82,400
- FNY INVESTMENT ADVISERS, LLC removed 20,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $51,400
- CITADEL ADVISORS LLC added 15,355 shares (+inf%) to their portfolio in Q3 2025, for an estimated $30,710
- OSAIC HOLDINGS, INC. added 152 shares (+inf%) to their portfolio in Q3 2025, for an estimated $304
- UBS GROUP AG removed 115 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $230
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$OKYO Analyst Ratings
Wall Street analysts have issued reports on $OKYO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/23/2025
To track analyst ratings and price targets for $OKYO, check out Quiver Quantitative's $OKYO forecast page.
Full Release
LONDON and NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces that Panetta Partners Limited, an entity in which Gabriele Cerrone, Executive Chairman has a beneficial interest, has acquired 82,018 of the Company’s ordinary shares on NASDAQ, bringing his total holding to 10,464,695 shares.
About Urcosimod (Formerly called OK-101)
Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating ocular diseases. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to potentially enhance the efficacy of urcosimod within the ocular environment. Urcosimod showed clear statistical significance in multiple endpoints in a 240-patient completed Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease, and just completed a randomized, placebo-controlled, double-masked Phase 2 trial of urcosimod to treat neuropathic corneal pain.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain and dry eye disease, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. A Phase 2 trial of urcosimod to treat neuropathic corneal pain patients was just completed by OKYO.
For further information, please visit www.okyopharma.com .
Inquiries:
| Business Development & Investor Relations | Paul Spencer |
+44 (0)20 7495 2379
|
